XML 63 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Millions, unless otherwise specified
12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Cash flows from operating activities:      
Net income $ 592us-gaap_ProfitLoss [1] $ 883us-gaap_ProfitLoss [1] $ 592us-gaap_ProfitLoss
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 314us-gaap_DepreciationDepletionAndAmortization 283us-gaap_DepreciationDepletionAndAmortization 287us-gaap_DepreciationDepletionAndAmortization
Provision for doubtful accounts 296us-gaap_ProvisionForDoubtfulAccounts 270us-gaap_ProvisionForDoubtfulAccounts 269us-gaap_ProvisionForDoubtfulAccounts
Deferred income tax provision 23us-gaap_DeferredIncomeTaxExpenseBenefit 19us-gaap_DeferredIncomeTaxExpenseBenefit 7us-gaap_DeferredIncomeTaxExpenseBenefit
Stock-based compensation expense 51us-gaap_ShareBasedCompensation 28us-gaap_ShareBasedCompensation 50us-gaap_ShareBasedCompensation
Excess tax benefits from stock-based compensation arrangements 0us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities (4)us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities (4)us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
Gain on sale of royalty rights 0dgx_GainonSaleofRoyaltyRights (474)dgx_GainonSaleofRoyaltyRights 0dgx_GainonSaleofRoyaltyRights
Asset impairment and loss on sale of business, net 0dgx_AssetImpairmentAndLossOnSaleOfBusiness 17dgx_AssetImpairmentAndLossOnSaleOfBusiness 86dgx_AssetImpairmentAndLossOnSaleOfBusiness
Other, net (12)us-gaap_OtherNoncashIncomeExpense 2us-gaap_OtherNoncashIncomeExpense (8)us-gaap_OtherNoncashIncomeExpense
Changes in operating assets and liabilities:      
Accounts receivable (312)us-gaap_IncreaseDecreaseInAccountsReceivable (247)us-gaap_IncreaseDecreaseInAccountsReceivable (243)us-gaap_IncreaseDecreaseInAccountsReceivable
Accounts payable and accrued expenses 68us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities (21)us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities (13)us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
Income taxes payable (84)us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable (93)us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable 100us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable
Termination of interest rate swap agreements 0dgx_TerminationOfInterestRateSwapAgreements 0dgx_TerminationOfInterestRateSwapAgreements 72dgx_TerminationOfInterestRateSwapAgreements
Other assets and liabilities, net 2us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet (11)us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet (8)us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet
Net cash provided by operating activities 938us-gaap_NetCashProvidedByUsedInOperatingActivities 652us-gaap_NetCashProvidedByUsedInOperatingActivities 1,187us-gaap_NetCashProvidedByUsedInOperatingActivities
Cash flows from investing activities:      
Business acquisitions, net of cash acquired (728)us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired (213)us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired (51)us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired
Proceeds from sale of businesses 0us-gaap_ProceedsFromDivestitureOfBusinesses 296us-gaap_ProceedsFromDivestitureOfBusinesses 0us-gaap_ProceedsFromDivestitureOfBusinesses
Proceeds from sale of royalty rights 0dgx_ProceedsfromDivestitureofRoyaltyRights 474dgx_ProceedsfromDivestitureofRoyaltyRights 0dgx_ProceedsfromDivestitureofRoyaltyRights
Capital expenditures (308)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (231)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (182)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Decrease in investments and other assets 11us-gaap_PaymentsForProceedsFromOtherInvestingActivities 2us-gaap_PaymentsForProceedsFromOtherInvestingActivities 16us-gaap_PaymentsForProceedsFromOtherInvestingActivities
Net cash (used in) provided by investing activities (1,025)us-gaap_NetCashProvidedByUsedInInvestingActivities 328us-gaap_NetCashProvidedByUsedInInvestingActivities (217)us-gaap_NetCashProvidedByUsedInInvestingActivities
Cash flows from financing activities:      
Proceeds from borrowings 2,018us-gaap_ProceedsFromIssuanceOfDebt 896us-gaap_ProceedsFromIssuanceOfDebt 715us-gaap_ProceedsFromIssuanceOfDebt
Repayments of debt (1,647)us-gaap_RepaymentsOfDebt (900)us-gaap_RepaymentsOfDebt (1,369)us-gaap_RepaymentsOfDebt
Purchases of treasury stock (132)us-gaap_PaymentsForRepurchaseOfCommonStock (1,037)us-gaap_PaymentsForRepurchaseOfCommonStock (200)us-gaap_PaymentsForRepurchaseOfCommonStock
Exercise of stock options 78us-gaap_ProceedsFromStockOptionsExercised 138us-gaap_ProceedsFromStockOptionsExercised 162us-gaap_ProceedsFromStockOptionsExercised
Excess tax benefits from stock-based compensation arrangements 0us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities 4us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities 4us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
Dividends paid (187)us-gaap_PaymentsOfDividendsCommonStock (185)us-gaap_PaymentsOfDividendsCommonStock (108)us-gaap_PaymentsOfDividendsCommonStock
Distributions to noncontrolling interests (31)us-gaap_PaymentsOfDividendsMinorityInterest (32)us-gaap_PaymentsOfDividendsMinorityInterest (38)us-gaap_PaymentsOfDividendsMinorityInterest
Other financing activities, net (7)us-gaap_ProceedsFromPaymentsForOtherFinancingActivities 10us-gaap_ProceedsFromPaymentsForOtherFinancingActivities 12us-gaap_ProceedsFromPaymentsForOtherFinancingActivities
Net cash provided by (used in) financing activities 92us-gaap_NetCashProvidedByUsedInFinancingActivities (1,106)us-gaap_NetCashProvidedByUsedInFinancingActivities (822)us-gaap_NetCashProvidedByUsedInFinancingActivities
Net change in cash and cash equivalents 5us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease (126)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 148us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Change in cash and cash equivalents included in current assets held for sale 0us-gaap_CashDivestedFromDeconsolidation 17us-gaap_CashDivestedFromDeconsolidation (17)us-gaap_CashDivestedFromDeconsolidation
Cash and cash equivalents, beginning of year 187us-gaap_CashAndCashEquivalentsAtCarryingValue 296us-gaap_CashAndCashEquivalentsAtCarryingValue 165us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash and cash equivalents, end of year $ 192us-gaap_CashAndCashEquivalentsAtCarryingValue $ 187us-gaap_CashAndCashEquivalentsAtCarryingValue $ 296us-gaap_CashAndCashEquivalentsAtCarryingValue
[1] In December 2012, the Company committed to a plan to sell HemoCue and completed the sale of OralDNA. During the third quarter of 2006, the Company completed its wind down of NID and classified the operations of NID as discontinued operations. Results of operations have been prepared to report the results of HemoCue, OralDNA and NID as discontinued operations for all periods presented (see Note 18).